Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial
Authors
Keywords
-
Journal
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
Volume -, Issue -, Pages 1-10
Publisher
Informa UK Limited
Online
2020-12-10
DOI
10.1080/00365521.2020.1856405
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease
- (2019) Konstantinos Papamichael et al. Journal of Crohns & Colitis
- Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
- (2019) Konstantinos Papamichael et al. Clinical Gastroenterology and Hepatology
- Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease
- (2019) Samuel Raimundo Fernandes et al. INFLAMMATORY BOWEL DISEASES
- Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease
- (2018) Geert D’Haens et al. GASTROENTEROLOGY
- DOP047 Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn’s disease: pharmacokinetic–pharmacodynamic analysis of TAILORIX
- (2018) E Dreesen et al. Journal of Crohns & Colitis
- Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis
- (2018) David Kevans et al. Journal of Crohns & Colitis
- American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
- (2017) Joseph D. Feuerstein et al. GASTROENTEROLOGY
- Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial
- (2017) Thomas Van Stappen et al. GUT
- A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease
- (2017) Johannan F. Brandse et al. INFLAMMATORY BOWEL DISEASES
- Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients
- (2016) Marla C. Dubinsky et al. AAPS Journal
- Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis
- (2016) B. Ungar et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2016) Bella Ungar et al. Clinical Gastroenterology and Hepatology
- Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis
- (2016) Johannan F. Brandse et al. Clinical Gastroenterology and Hepatology
- Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis
- (2016) Konstantinos Papamichael et al. Clinical Gastroenterology and Hepatology
- An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis
- (2015) David J. Gibson et al. Clinical Gastroenterology and Hepatology
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- Dashboard Systems: Implementing Pharmacometrics from Bench to Bedside
- (2014) Diane R. Mould et al. AAPS Journal
- A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease
- (2014) B. G. Levesque et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy
- (2014) T. W. Felton et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
- (2014) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
- (2014) Freddy Cornillie et al. GUT
- Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease
- (2014) Iris Dotan et al. INFLAMMATORY BOWEL DISEASES
- P470 High infliximab trough levels are associated with impaired quality of life in IBD patients in clinical and biochemical remission on maintenance IFX therapy
- (2014) M. Löwenberg et al. Journal of Crohns & Colitis
- Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays
- (2012) N. Vande Casteele et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
- (2012) Geert DʼHaens et al. INFLAMMATORY BOWEL DISEASES
- Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
- (2012) Martin Bortlik et al. Journal of Crohns & Colitis
- Review article: loss of response to anti-TNF treatments in Crohn’s disease
- (2011) S. Ben-Horin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search